Hypometabolism as a therapeutic target in Alzheimer's disease

por Costantini, Lauren C, Barr, Linda J, Vogel, Janet L, Henderson, Samuel T
Publicado 2008

Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial

por Henderson, Samuel T, Vogel, Janet L, Barr, Linda J, Garvin, Fiona, Jones, Julie J, Costantini, Lauren C
Publicado 2009